我院生殖与泌尿男科门诊用药分析

目的 分析我院生殖与泌尿男科门诊的用药情况，为药物利用综合评价及临床合理用药提供参考。方法 采用回顾性调查方法，对我院2018—2019年生殖与泌尿男科门诊用药情况按药理分类、销售金额和用药频度（DDDs）及用药循证依据等进行统计分析。结果 2018年、2019年药品销售排前三位类别分别是：中成药（78.42%、69.74%）、心血管系统用药（9.09%、18.6%）、促性腺激素类（6.45%、7.25%），以上三类占据男科用药主导地位，其销售合计占比分别为93.96%、95.59%；各类药品销售金额排序相对稳定，用药频度排序部分发生变化。生精片、龙鹿丸、胰激肽原酶肠溶片在2年内销售均列单品前三位。用药频次前三位：2018年为来曲唑片、生精片、胰激肽原酶肠溶片；2019年为胰激肽原酶肠溶片、龙鹿丸、四维葡锌胶丸。结论 山大生殖医院男性不育症致孕率居国内领先，其中药物的辅助治疗发挥了积极作用，用药评价分析表明整体用药结构基本符合我院生殖与泌尿男科临床诊疗方向，但中成药治疗周期较长、疗效尚缺乏高级别循证依据，有待于进一步的综合评价与临床研究。此外，尚需加强辅助用药的临床监管、提高合理用药水平。

Analysis of drugs used in male outpatient department of reproductive and urological in our hospital

Objective To analyze the drug use in male reproductive and urological outpatient department of our hospital so as to provide reference for comprehensive evaluation of drug use and clinical rational drug use.Methods Retrospective investigation is adopted to statistically analyze the drug use in reproductive and urological male outpatient department from 2018 to 2019 according to pharmacological classification of sales amount,DDDs and evidence-based basis of drug use.Results The top three categories of drug sales in 2018 and 2019 were Chinese patent medicine (78.42% and 69.74%), cardiovascular system drugs (9.09% and 18.6%), gonadotropins (6.45% and 7.25%), and the above three categories occupied the dominant position in male medicine, accounting for 93.96% and 95.59% respectively. The ranking of sales amount of the drugs mentioned is relatively stable, while the ranking of DDDs changes partially.Shengjing Tablets,Dragon Deer Pill and Pancreatic Kininogenase Enteric-coated Tablets are all listed in the top three in sales within the 2 years. The top three drug use frequencies were Letrozole Tablets,Shengjing Tablets and Pancreatic Kininogenase Enteric-coated Tablets in 2018.In 2019,Pancreatic Kininogenase Enteric-coated Tablets,Dragon Deer Pill and Four-dimensional Zinc Gluconate Capsules rank the top three.Conclusions The pregnancy rate of male infertility in Shanda Reproductive Hospital is the highest in China, in which the adjuvant therapy of drugs has played a positive role. Drug evaluation analysis shows that the overall drug structure basically conforms to the clinical diagnosis and treatment direction of reproductive and urological andrology department in our hospital.However, the treatment cycle of Chinese patent medicine is long and the curative effect lacks high-level evidence-based basis needs further comprehensive evaluation and clinical research. In addition, it is necessary to strengthen the clinical supervision of adjuvant drugs and improve the level of rational drug use.